Related Experiment Videos
Data-Driven Commissioning to Reduce Type 2 Diabetes Related Health Disparities in The Netherlands: Using Key
Els Roorda1, Marc Bruijnzeels1, Jeroen Struijs1,2
1Department of Public Health and Primary Care (PHEG), Leiden University Medical Centre (LUMC), 2300 RC Leiden, The Netherlands.
Healthcare (Basel, Switzerland)
|June 26, 2026
Summary
Dutch health insurers use claims data to reduce health disparities in type 2 diabetes care. Decision context, not data capabilities, significantly influences their ability to address these inequalities.
Area of Science:
- Healthcare Management
- Health Disparities Research
- Health Informatics
Background:
- Health disparities in type 2 diabetes contribute significantly to healthcare utilization.
- Dutch private, not-for-profit health insurers aim to improve care accessibility.
- The study investigates insurers' use of claims data in commissioning to mitigate these disparities.
Purpose of the Study:
- To identify factors influencing the reduction of health disparities through data-driven commissioning.
- To understand the role of data capabilities and decision context in this process.
Main Methods:
- Key informant group interviews were conducted.
- Data analysis employed a hybrid deductive-inductive approach using the 6SQIuD framework.
- Results were validated through saturation, member, and expert checks.
Main Results:
- 79 factors were identified: 3 related to data capabilities and 76 to decision context.
- Fifteen main factors emerged across socio-cultural, system, organizational, and interpersonal levels.
- Decision context factors centered on equality, quality, and organizational sustainability.
Conclusions:
- Commissioners' ability to reduce disparities is influenced by decision context, not primarily data capabilities.
- Paradoxes identified include equal access leading to unequal outcomes and evidence-based interventions limiting disparity reduction.
- Further policy analysis is needed to understand systemic and organizational conditions supporting disparity reduction efforts.
Related Concept Videos
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...